Summit lead drug granted China label expansion (SMMT:NASDAQ)
· seekingalpha.com
Summit Therapeutics (SMMT) stock rises as China approves a label expansion for lead drug ivonescimab, developed with Akeso (AKESF). Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...